[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647293":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":18,"responsibleParty":31,"collaborators":18,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":18,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":18,"enrollmentInfo":44,"targetDuration":18,"studyType":47,"phases":48,"briefSummary":51,"conditions":52,"keywords":18,"overallStatus":55,"whyStopped":18,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":18},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ginkgo biloba group","EXPERIMENTAL","Ginkgo biloba group: 25 patients will receive Ginkgo biloba treatment (120 mg twice daily for 12 weeks) in addition to their standard treatment.",[13],"Drug: Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","NO_INTERVENTION","Control group: 25 patients will receive standard treatment for 12 weeks.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM","Ginkgo biloba leaf extract (GBLE) has an antioxidant action as a free radical scavenger, an improving effect on blood flow or microcirculation, and a stimulating effect on neurotransmitters. Besides a direct scavenging action on active oxygen species, GBLE exerts an anti-inflammatory effect on inflammatory cells by suppressing the production of active oxygen and nitrogen species. GBLE inhibited the increase in the products of the oxidative decomposition low-density lipoprotein (LDL), reduced the cell death in various types of neuropathies, and prevented the oxidative damage to mitochondria",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"noran sameh ahmed, bachelor degree in pharmacy","CONTACT","201068397368","nuran.sameh@pharma.asu.edu.eg",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Nuran Sameh","noran sameh ahmed","100647293","phase-2-the-effect-of-ginkgo-biloba-on-rheumatoid-arthritis-patients-100647293",false,"NCT07709312","the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients","The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients","Inclusion Criteria:1. Adult patients (older than 18 years) 2. With moderate to high disease activity defined as DAS-28 score ≥ 3.2 3. Patients receiving stable regimen of one or more csDMARDs for the past 6 months\n\n\\-\n\nExclusion Criteria:\n\n\\- 1. Patients with known hypersensitivity to Ginkgo biloba 2. Patients receiving Ginkgo biloba for any other indications 3. Patients on biologic DMARDs 4. Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin), 5. Patients with any of the following comorbidities: congestive heart failure, history of myocardial infarction, severe anemia, active infections, other inflammatory diseases, and malignancies.\n\n6\\. Patients with other autoimmune diseases","ALL","18 Years",{"count":45,"type":46},50,"ESTIMATED","INTERVENTIONAL",[49,50],"PHASE2","PHASE3","this study aims to measure The Effect of Gingko Biloba on the Clinical Outcome of Rheumatoid Arthritis Patients ,the outcomes are hsCRp,calprotectin,DAS-28,HAQ-DI",[53,54],"Rheumatoid Arthritis (RA)","Manegmentof Rheumatoid Arthritis","NOT_YET_RECRUITING","2026-07-12",{"date":58,"type":59},"2026-07-16","ACTUAL",{"date":61,"type":46},"2026-07-15",{"date":63,"type":46},"2026-10-15",{"name":5,"class":6}]